Key Highlights

  • Fox (NASDAQ:FOXA) secured antitrust sign-off from the Justice Department on its USD 22 billion Roku purchase, a deal it had already closed on November 6.
  • Greenfire Resources jumped roughly 38% on a Strathcona buyout that offers CAD 11.00 in cash, a level about 39% over its November 6 close.
  • Surgery Partners gained around 14% after its buyer lifted the price to USD 25.00 per share, and a competing USD 28.00 proposal was deemed not superior.
  • argenx committed up to roughly USD 1.15 billion for Unnatural Products, while Charles River will acquire Frontage units for around USD 470 million.

1. Fox (NASDAQ:FOXA)

Antitrust review of Fox's (NASDAQ:FOXA) USD 22 billion Roku Takeover wrapped up, with the Justice Department's outcome surfacing over the November 7 and 8 weekend, 2026. The transaction had been finished on Friday, November 6, well ahead of the first-half 2027 closure that was initially pencilled in. Approval carried strings: the company pledged to keep hosting non-Fox channels on Roku for a minimum of three years and to provide competing streamers equitable access and placement. Fox stock gained 1.6% on November 9 as the regulatory cloud dissipated. As the biggest transaction on this roster, its worth now hinges on integration and the USD 400 million in targeted savings. Roku's exit from the S&P MidCap 400 also created an opening that James Hardie takes on November 11.

2. Greenfire Resources (NYSE:GFR)

Shares of Greenfire Resources (NYSE:GFR) surged about 38% after the November 8 agreement to be acquired by Strathcona Resources, which puts an Enterprise value between CAD 2.7 billion and CAD 2.9 billion on the company, with roughly CAD 550 million of net Debt inside that figure. Shareholders may opt for 0.25 of a Strathcona share, valued near CAD 9.09 and carrying a premium of around 15%, or receive CAD 11.00 in cash, which sits roughly 39% above the November 6 close, with no proration applied. The largest holder owns roughly 72% of Greenfire and around 57% of Strathcona, and it will take shares. Together the businesses would generate around 153,000 barrels of oil equivalent per day, with synergies near CAD 75 million annually. Cash takers collect the most value, though the transaction requires a two-thirds vote and separate minority approval in January 2027, with closing expected early that year.

3. Surgery Partners (NASDAQ:SGRY)

A contest for Surgery Partners (NASDAQ:SGRY) intensified, lifting the shares roughly 14%. On November 9 the agreed acquirer moved its price to USD 25.00 per share from USD 23.50, which raises enterprise value to around USD 6 billion, and layered on a 10% annual ticking charge that may push the total to USD 26.61 at most should completion slide to the October 2027 outside date. An alternative USD 28.00 cash offer was rejected by the special committee as not superior, owing to a longer and less assured closing, regulatory exposure and softer safeguards. The biggest shareholder, holding about 39%, entered a voting agreement and will roll over its stake. Shares ended near USD 25.98, which is above the deal price, signaling expectations of another increase or a renewed rival approach. Closing is targeted for early 2027.

4. argenx (NASDAQ:ARGX)

Pledging USD 550 million upfront plus contingent value rights, argenx (NASDAQ:ARGX) will purchase Unnatural Products, a privately held drug discovery firm in Santa Cruz, California, announced on November 9. Milestone payments linked to development and regulatory progress could lift the total to around USD 1.15 billion, and closing should occur by late 2026. The target builds macrocyclic peptides, compounds meant to pair antibody-like precision with oral or simpler administration. Four major pharmaceutical partnerships, including ones with Novartis, Merck and BridgeBio, have been struck with the platform within under five years, and argenx previously owned a minority position. This is a technology wager, not an earnings-driven transaction, so the payoff will emerge years out through argenx's upcoming immunology pipeline.

5. Charles River Laboratories (NYSE:CRL)

On November 9, Charles River Laboratories (NYSE:CRL) reached a deal to take over Frontage's bioanalysis and drug metabolism and pharmacokinetics operations for approximately USD 470 million cash, along with up to USD 75 million of performance-linked payments. Those Assets operate from Exton, Pennsylvania, spread across two facilities of around 150,000 square feet, employing about 340 people and hosting a certified central lab. They produced roughly 40% of Frontage's USD 256.7 million 2025 revenue, which suggests annual sales near USD 100 million, making the price close to five times sales, a figure calculated by us. Completion is slated for the first half of 2027 pending approvals, including one in Hong Kong. The transaction should be neutral to adjusted EPS in 2027, turning accretive after that. It broadens clinical-stage testing capacity, a dependable but smaller contribution than the other transactions here.

Where Things Stand

Among these five November 9 transactions, Greenfire holders gain the quickest benefit through a cash option roughly 39% over the prior close. Surgery Partners shareholders profit from the contest, since shares trade above the lifted USD 25.00 price. The USD 22 billion Roku transaction from Fox is the biggest here and already cleared by regulators, so the payoff rides on integration and cost cuts. argenx and Charles River are acquiring capabilities, namely a peptide discovery platform and scale in clinical testing. Completion dates range from late 2026 into the first half of 2027.